Transport of nanocarriers to brain for treatment of glioblastoma multiforme: Routes and challenges

Trivedi, Shubha Sagar; Bhoyar, Vidyadevi; Akojwar, Natasha; Belgamwar, Veena S.

doi:10.1016/j.nwnano.2023.100005

Cited by 6 publications

(1 citation statement)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Beyond the composition of the NP, the mode of administration also affects the tissue distribution of NPs. Overall, the administration of NPs can be achieved by intravenous injection, intra-tumor injection, and intranasal administration [ 94 ]. These different modes of administration have various advantages or disadvantages.…”

Section: Manipulating the Bbbmentioning

confidence: 99%

Overcoming Barriers in Glioblastoma—Advances in Drug Delivery Strategies

ter Linden,

Abels,

van Solinge

et al. 2024

Cells

View full text Add to dashboard Cite

The world of cancer treatment is evolving rapidly and has improved the prospects of many cancer patients. Yet, there are still many cancers where treatment prospects have not (or hardly) improved. Glioblastoma is the most common malignant primary brain tumor, and even though it is sensitive to many chemotherapeutics when tested under laboratory conditions, its clinical prospects are still very poor. The blood–brain barrier (BBB) is considered at least partly responsible for the high failure rate of many promising treatment strategies. We describe the workings of the BBB during healthy conditions and within the glioblastoma environment. How the BBB acts as a barrier for therapeutic options is described as well as various approaches developed and tested for passing or opening the BBB, with the ultimate aim to allow access to brain tumors and improve patient perspectives.

show abstract

Section: Manipulating the Bbbmentioning

confidence: 99%